Back to Stakeholders
Care Delivery & Psychedelic FacilitationClinical Care Delivery OrganizationsHealth Systems & Hospitals
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchUniversities and Colleges without Dedicated Psychedelic Research Groups
Care Delivery & Psychedelic FacilitationClinical Care Delivery Organizations
Care Delivery & Psychedelic Facilitation
Research, Drug Development & Manufacturing

CHU de Quebec-Universite Laval

Canada
1 Trial

CHU de Québec–Université Laval is Quebec City's largest university hospital network, affiliated with Université Laval and serving as a major clinical research hub. It hosts the P3A Study Group led by Dr. Michel Dorval (Oncology Division), conducting a psilocybin-assisted psychotherapy trial for existential distress in patients with advanced cancer.

Academic Research

0 papers

Published Papers

0

Trial Involvement

1

Distinct Focus Topics

0

Latest Publication

Unknown

Quick Facts

Type
Other
HQ
Canada
Website
Visit

Collaborated Trials

1
RecruitingI, II

Psilocybin for Psychological and Existential Distress in Palliative Care

Start Date
Compounds
Psilocybin